A clinical formulation indicated for Men's Health. Targeted physiological inhibition promotes the reduction of prostate enlargement symptoms and secondary urinary discomfort.
A dual enzyme inhibitor intended to manage symptoms of an enlarged prostate by relieving urinary discomfort and developed to support prostate size reduction.
Mechanism of Action
It blocks both Type I and Type II forms of the enzyme 5-alpha-reductase. This significantly reduces the levels of dihydrotestosterone (DHT) in the blood and prostate, leading to a reduction in prostate size and improved urinary flow.
Route of Administration
Oral
Onset Time
3–6 months for symptom improvement
Duration
Very long-acting
Contraindications
Pregnancy, Women of childbearing age, Children, Allergy to dutasteride
Severe Adverse Events
Persistent sexual side effects, High-grade prostate cancer risk, Severe skin reactions
Information for Avodart is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
